Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation

Giovanni Caocci, Fabio Efficace, Francesca Ciotti, Maria Grazia Roncarolo, Adriana Vacca, Eugenia Piras, Roberto Littera, Raji Suleiman Dawood Markous, Gary Stephen Collins, Fabio Ciceri, Franco Mandelli, Sarah Marktel, Giorgio La Nasa

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in 28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy. The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality, and rejection were 89.3%, 78.6%, 10.9% and 14.3%, respectively. The cumulative incidence of acute and chronic graft-versus-host disease (GVHD) was 36% and 18%, respectively. Physical functioning declined significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P = .02), but then increased significantly up to 18 months after HSCT (median score, 93.7; P = .04). Agreement between child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with lower HRQoL scores over time (P = .02). The child-self and parent-proxy reports showed improved HRQoL in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based data to further support clinical decision making in this area.

Original languageEnglish
Pages (from-to)861-866
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

beta-Thalassemia
Hematopoietic Stem Cell Transplantation
Quality of Life
Pediatrics
Proxy
Graft vs Host Disease
Thalassemia
Survival
Italy
Transplantation
Parents
Mortality
Incidence

Keywords

  • Child self-report
  • Parent-proxy report
  • Pediatric Quality of Life Inventory

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation. / Caocci, Giovanni; Efficace, Fabio; Ciotti, Francesca; Roncarolo, Maria Grazia; Vacca, Adriana; Piras, Eugenia; Littera, Roberto; Dawood Markous, Raji Suleiman; Collins, Gary Stephen; Ciceri, Fabio; Mandelli, Franco; Marktel, Sarah; La Nasa, Giorgio.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 6, 06.2011, p. 861-866.

Research output: Contribution to journalArticle

Caocci, G, Efficace, F, Ciotti, F, Roncarolo, MG, Vacca, A, Piras, E, Littera, R, Dawood Markous, RS, Collins, GS, Ciceri, F, Mandelli, F, Marktel, S & La Nasa, G 2011, 'Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 17, no. 6, pp. 861-866. https://doi.org/10.1016/j.bbmt.2010.09.011
Caocci, Giovanni ; Efficace, Fabio ; Ciotti, Francesca ; Roncarolo, Maria Grazia ; Vacca, Adriana ; Piras, Eugenia ; Littera, Roberto ; Dawood Markous, Raji Suleiman ; Collins, Gary Stephen ; Ciceri, Fabio ; Mandelli, Franco ; Marktel, Sarah ; La Nasa, Giorgio. / Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 6. pp. 861-866.
@article{d7f1c3338f5648de935a1b7fa8e5e618,
title = "Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation",
abstract = "Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in 28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy. The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality, and rejection were 89.3{\%}, 78.6{\%}, 10.9{\%} and 14.3{\%}, respectively. The cumulative incidence of acute and chronic graft-versus-host disease (GVHD) was 36{\%} and 18{\%}, respectively. Physical functioning declined significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P = .02), but then increased significantly up to 18 months after HSCT (median score, 93.7; P = .04). Agreement between child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with lower HRQoL scores over time (P = .02). The child-self and parent-proxy reports showed improved HRQoL in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based data to further support clinical decision making in this area.",
keywords = "Child self-report, Parent-proxy report, Pediatric Quality of Life Inventory",
author = "Giovanni Caocci and Fabio Efficace and Francesca Ciotti and Roncarolo, {Maria Grazia} and Adriana Vacca and Eugenia Piras and Roberto Littera and {Dawood Markous}, {Raji Suleiman} and Collins, {Gary Stephen} and Fabio Ciceri and Franco Mandelli and Sarah Marktel and {La Nasa}, Giorgio",
year = "2011",
month = "6",
doi = "10.1016/j.bbmt.2010.09.011",
language = "English",
volume = "17",
pages = "861--866",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation

AU - Caocci, Giovanni

AU - Efficace, Fabio

AU - Ciotti, Francesca

AU - Roncarolo, Maria Grazia

AU - Vacca, Adriana

AU - Piras, Eugenia

AU - Littera, Roberto

AU - Dawood Markous, Raji Suleiman

AU - Collins, Gary Stephen

AU - Ciceri, Fabio

AU - Mandelli, Franco

AU - Marktel, Sarah

AU - La Nasa, Giorgio

PY - 2011/6

Y1 - 2011/6

N2 - Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in 28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy. The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality, and rejection were 89.3%, 78.6%, 10.9% and 14.3%, respectively. The cumulative incidence of acute and chronic graft-versus-host disease (GVHD) was 36% and 18%, respectively. Physical functioning declined significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P = .02), but then increased significantly up to 18 months after HSCT (median score, 93.7; P = .04). Agreement between child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with lower HRQoL scores over time (P = .02). The child-self and parent-proxy reports showed improved HRQoL in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based data to further support clinical decision making in this area.

AB - Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in 28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy. The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality, and rejection were 89.3%, 78.6%, 10.9% and 14.3%, respectively. The cumulative incidence of acute and chronic graft-versus-host disease (GVHD) was 36% and 18%, respectively. Physical functioning declined significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P = .02), but then increased significantly up to 18 months after HSCT (median score, 93.7; P = .04). Agreement between child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with lower HRQoL scores over time (P = .02). The child-self and parent-proxy reports showed improved HRQoL in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based data to further support clinical decision making in this area.

KW - Child self-report

KW - Parent-proxy report

KW - Pediatric Quality of Life Inventory

UR - http://www.scopus.com/inward/record.url?scp=79956038028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956038028&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.09.011

DO - 10.1016/j.bbmt.2010.09.011

M3 - Article

VL - 17

SP - 861

EP - 866

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -